<DOC>
	<DOC>NCT00040521</DOC>
	<brief_summary>The purpose of this study is to assess the activity of multiple doses of oral rhIL-11 in patients with active Crohn's disease (Crohn's Disease Activity Index [CDAI] score from 220-400).</brief_summary>
	<brief_title>Study Evaluating rhIL-11 in Active Crohn's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Oprelvekin</mesh_term>
	<criteria>Documented, signed and dated informed consent to participate in this trial prior to any study related procedures being performed. Men and women age 16 years and over. Diagnosis of Crohn's disease for at least 6 months that has been appropriately documented and confirmed by radiological studies, endoscopy (with histological examination preferred), or surgical pathology (Patients with a diagnosis of Crohn's disease for less than 6 months may be included if the diagnosis is confirmed by a biopsy characteristic of Crohn's disease) Use of the following medications within the specified time period prior to randomization: Nonsteroidal antiinflammatory drugs (NSAIDs; including Cyclooxygenase2 [COX2] inhibitors and &gt;500 mg/day acetylsalicylic acid) Codeinecontaining compounds Corticosteroid enemas</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Crohn's Disease</keyword>
	<keyword>Active Crohns Disease</keyword>
</DOC>